Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) Profit After Tax (2016 - 2025)

CytomX Therapeutics' Profit After Tax history spans 12 years, with the latest figure at -$26.5 million for Q4 2025.

  • For Q4 2025, Profit After Tax fell 240.44% year-over-year to -$26.5 million; the TTM value through Dec 2025 reached -$17.4 million, down 154.5%, while the annual FY2025 figure was -$17.4 million, 154.5% down from the prior year.
  • Profit After Tax reached -$26.5 million in Q4 2025 per CTMX's latest filing, down from -$14.2 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $23.5 million in Q1 2025 to a low of -$34.8 million in Q4 2021.
  • Average Profit After Tax over 5 years is -$10.1 million, with a median of -$7.7 million recorded in 2022.
  • The largest YoY upside for Profit After Tax was 2155.2% in 2024 against a maximum downside of 501.1% in 2024.
  • A 5-year view of Profit After Tax shows it stood at -$34.8 million in 2021, then skyrocketed by 74.8% to -$8.8 million in 2022, then surged by 109.54% to $837000.0 in 2023, then soared by 2155.2% to $18.9 million in 2024, then plummeted by 240.44% to -$26.5 million in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Profit After Tax are -$26.5 million (Q4 2025), -$14.2 million (Q3 2025), and -$154000.0 (Q2 2025).